Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Entrectinib in NTRK fusion-positive non-small cell lung cancer

Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain

Entrectinib in NTRK fusion-positive non-small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )

The role of afatinib in patients with EGFR NSCLC

Dr Antonio Passaro - European Institute of Oncology, Milan, Italy

The role of afatinib in patients with EGFR NSCLC ( Dr Antonio Passaro - European Institute of Oncology, Milan, Italy )

Accelerated tumour growth due to immunotherapy: Fact or fiction?

Dr Marina Garassino - National Tumor Institute, Milan, Italy

Accelerated tumour growth due to immunotherapy: Fact or fiction? ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )

Biomarkers of systemic inflammation linked to reduced clinical activity of...

Luciana Molinero - Genentech, San Francisco, USA

Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC ( Luciana Molinero - Genentech, San Francisco, USA )

KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after...

Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea

KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after two or more lines of prior therapy ( Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea )

Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative...

Dr Constantia Pantelidou - Dana Farber Cancer Institute, Boston, USA

Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer ( Dr Constantia Pantelidou - Dana Farber Cancer Institute, Boston, USA )

Efficacy and immune correlates of the SRA737 plus LDG regimen in combination...

Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas

Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model ( Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas )

Lymphodepleting chemotherapy in order to safely improve the expansion of HER2...

Prof Shoba Navai - Baylor College of Medicine, Houston, USA

Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas ( Prof Shoba Navai - Baylor College of Medicine, Houston, USA )

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1...

Dr James Gulley - National Cancer Institute, Bethesda, USA

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies ( Dr James Gulley - National Cancer Institute, Bethesda, USA )

Using T cell engineering plus triple checkpoint blockade to enhance the...

Dr Kristin Anderson - Fred Hutchinson Cancer Research Center, Seattle, USA

Using T cell engineering plus triple checkpoint blockade to enhance the efficacy of adoptive immunotherapy in ovarian cancer ( Dr Kristin Anderson - Fred Hutchinson Cancer Research Center, Seattle, USA )

Using regionally delivered autologous mesothelin-targeted CAR T cells in the...

Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA

Using regionally delivered autologous mesothelin-targeted CAR T cells in the treatment of malignant pleural disease ( Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA )

Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine...

Prof Sandip Patel - UC San Diego, San Diego, USA

Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine carcinoma ( Prof Sandip Patel - UC San Diego, San Diego, USA )

More from ecancer